← Leaderboards
Ludmila S. Belayev
Lsu Health Sciences Center
$3,706,231
Attributed
$5,845,636
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $666.6K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,845,636 · 4
By mechanism
R01$5,845,636 · 4
Top collaborators
- Nicolas Guillermo Bazan12 shared
Most similar at Lsu Health Sciences Center
Same institution · by research overlap
- David Thoms Stark$124,930
- Tiffany Niemoller Eady$147,998
- Kristopher Graye Sheets$67,796
- Alberto Eugenio Musto$479,331
- Yongdong Zhou$396,003
Others in their field
Top investigators on “Ischemic Penumbra”
- David E Smith · Angion Biomedica Corporation$5,897,382
- Arjun G. Yodh · University Of Pennsylvania$5,524,298
- Phillip Zhe Sun · Emory University$4,232,642
- Sergei A Kirov · Boston University$3,495,182
- David M. Hasan · University Of Iowa$3,384,761
- Sandra J Hewett · University Of Connecticut Sch Of Med/Dnt$3,308,206
Research focus
Ischemic PenumbraResponseStrokeAgedRattusIschemiaMediatingIschemic StrokeNeuroprotectionDoseLongevityCerebral IschemiaStroke TherapyLipid MediatorRecoveryBlood - Brain Barrier AnatomyMagnetic Resonance ImagingBrainInflammationNeuronsOmega-3 Fatty AcidsBehavioralCell SurvivalMiddle Cerebral Artery Occlusion
Grant awards (18)
Neuroprotective lipid mediators target penumbra in experimental ischemic stroke$495,159
R01 · FY2025 · NS
Neuroprotective lipid mediators target penumbra in experimental ischemic stroke$481,617
R01 · FY2024 · NS
Docosanoids modulate homeostasis and cell survival after ischemic stroke$328,650
R01 · FY2023 · NS
Docosanoids modulate homeostasis and cell survival after ischemic stroke$328,650
R01 · FY2022 · NS
Novel combinatory therapy for experimental ischemic stroke$327,688
R01 · FY2022 · NS
Docosanoids modulate homeostasis and cell survival after ischemic stroke$328,650
R01 · FY2021 · NS
Novel combinatory therapy for experimental ischemic stroke$327,688
R01 · FY2021 · NS
Docosanoids modulate homeostasis and cell survival after ischemic stroke$328,650
R01 · FY2020 · NS
Novel combinatory therapy for experimental ischemic stroke$327,688
R01 · FY2020 · NS
Docosanoids modulate homeostasis and cell survival after ischemic stroke$338,932
R01 · FY2019 · NS
Novel combinatory therapy for experimental ischemic stroke$327,688
R01 · FY2019 · NS
Novel combinatory therapy for experimental ischemic stroke$337,751
R01 · FY2018 · NS
Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke$301,368
R01 · FY2014 · NS · contact PI
Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke$293,758
R01 · FY2013 · NS · contact PI
Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke$304,413
R01 · FY2012 · NS · contact PI
Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke$342,198
R01 · FY2011 · NS · contact PI
Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke$14,463
R01 · FY2011 · NS · contact PI
Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke$310,625
R01 · FY2010 · NS · contact PI